Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

Reduced Risk of Nocturnal-Confirmed Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 1 Diabetes Requiring High Doses of Basal Insulin: a Meta-analysis of 2 Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2013.08.160 ◽

2013 ◽

Vol 37 ◽

pp. S54

Author(s):

Helena W. Rodbard ◽

Yehuda Handelsman ◽

Stephen C.L. Gough ◽

Todd M. Hobbs ◽

Lars Korsholm ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Reduced Risk of Hypoglycemia with Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: Meta-Analysis of Five Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2012.07.399 ◽

2012 ◽

Vol 36 (5) ◽

pp. S57 ◽

Cited By ~ 2

Author(s):

Helena W. Rodbard ◽

Yehuda Handelsman ◽

Stephen Gough ◽

Jina Hahn ◽

Nathan Lassota ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Reduced Risk of Hypoglycemia with Insulin Degludec Versus Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: A Meta-Analysis of 5 Randomized Begin Trials

Endocrine Practice ◽

10.4158/ep13287.or ◽

2014 ◽

Vol 20 (4) ◽

pp. 285-292 ◽

Cited By ~ 36

Author(s):

Helena Rodbard ◽

Stephen Gough ◽

Wendy Lane ◽

Lars Korsholm ◽

Ditte-Marie Bretler ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Diabetes ◽

10.2337/db18-1057-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1057-P

Author(s):

SEAN D. SULLIVAN ◽

TIMOTHY S. BAILEY ◽

RONAN ROUSSEL ◽

FANG L. ZHOU ◽

ZSOLT BOSNYAK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Clinical Outcomes ◽

Real World ◽

Insulin Detemir ◽

Insulin Degludec ◽

Subgroup Analyses

Download Full-text

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1400011 ◽

2017 ◽

Vol 18 (17) ◽

pp. 1789-1798 ◽

Cited By ~ 14

Author(s):

Xiaoling Cai ◽

Xueying Gao ◽

Wenjia Yang ◽

Linong Ji

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Meta Analysis ◽

Insulin Degludec

Download Full-text

Acylated-based long-acting insulin analogues: Is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes

Diabetes & Metabolism ◽

10.1016/j.diabet.2014.10.001 ◽

2014 ◽

Vol 40 (6) ◽

pp. 483-484 ◽

Cited By ~ 1

Author(s):

L. Monnier ◽

C. Colette ◽

D. Owens

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Analogues ◽

Insulin Degludec ◽

Insulin Antibody ◽

Daily Insulin ◽

Acting Insulin ◽

Long Acting

Download Full-text

Insulin Degludec Results in Consistently Lower Rates of Nocturnal Hypoglycemia Despite Lower FPG Levels Compared to Insulin Glargine in Seven Trials with T1DM or T2DM

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2012.07.404 ◽

2012 ◽

Vol 36 (5) ◽

pp. S58-S59

Author(s):

David L. Russell-Jones ◽

Stefano Del Prato ◽

Mari-Anne Gall ◽

Nathan Lassota ◽

Michaela Diamant

Keyword(s):

Insulin Glargine ◽

Insulin Degludec ◽

Nocturnal Hypoglycemia

Download Full-text

Clinical Research of Insulin Glargine U300 basal‐bolus therapy and Insulin Degludec/Aspart Co‐Formulation in Type 2 Diabetes Mellitus: A Real World Experience (CRIGDA Study)

International Journal of Clinical Practice ◽

10.1111/ijcp.14377 ◽

2021 ◽

Author(s):

Savas Volkan Kisioglu ◽

Ahmet Suat Demir ◽

Damla Tufekci ◽

Yasemin Emur Gunay ◽

Hulya Coskun ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Clinical Research ◽

Insulin Glargine ◽

Real World ◽

Insulin Degludec ◽

Basal Bolus

Download Full-text

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Diabetes & Metabolism ◽

10.1016/j.diabet.2018.11.004 ◽

2019 ◽

Vol 45 (4) ◽

pp. 330-340 ◽

Cited By ~ 3

Author(s):

D.R. Owens ◽

T. S Bailey ◽

C.G. Fanelli ◽

J.-F. Yale ◽

G.B. Bolli

Keyword(s):

Insulin Glargine ◽

Clinical Relevance ◽

Insulin Degludec ◽

Clinical Interpretation

Download Full-text

A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes

Endocrine Journal ◽

10.1507/endocrj.ej16-0294 ◽

2017 ◽

Vol 64 (2) ◽

pp. 133-140 ◽

Cited By ~ 8

Author(s):

Tatsuhiko Urakami ◽

Yusuke Mine ◽

Masako Aoki ◽

Misako Okuno ◽

Junichi Suzuki

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Crossover Study ◽

Insulin Degludec ◽

Efficacy And Safety ◽

Randomized Crossover Study

Download Full-text